These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 19884297)

  • 1. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
    Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Ghogomu ET; Tugwell P
    CMAJ; 2009 Nov; 181(11):787-96. PubMed ID: 19884297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics for rheumatoid arthritis: an overview of Cochrane reviews.
    Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Tanjong Ghogomu E; Tugwell P
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007848. PubMed ID: 19821440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
    Jansen JP; Buckley F; Dejonckheere F; Ogale S
    Health Qual Life Outcomes; 2014 Jul; 12():102. PubMed ID: 24988902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse effects of biologics: a network meta-analysis and Cochrane overview.
    Singh JA; Wells GA; Christensen R; Tanjong Ghogomu E; Maxwell L; Macdonald JK; Filippini G; Skoetz N; Francis D; Lopes LC; Guyatt GH; Schmitt J; La Mantia L; Weberschock T; Roos JF; Siebert H; Hershan S; Lunn MP; Tugwell P; Buchbinder R
    Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD008794. PubMed ID: 21328309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologics for rheumatoid arthritis: an overview of Cochrane reviews.
    Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Ghogomu ET; Tugwell P
    Sao Paulo Med J; 2010; 128(5):309-10. PubMed ID: 21181074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.
    Wiens A; Venson R; Correr CJ; Otuki MF; Pontarolo R
    Pharmacotherapy; 2010 Apr; 30(4):339-53. PubMed ID: 20334454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.
    Nixon R; Bansback N; Brennan A
    Rheumatology (Oxford); 2007 Jul; 46(7):1140-7. PubMed ID: 17478472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
    Yun H; Xie F; Delzell E; Chen L; Levitan EB; Lewis JD; Saag KG; Beukelman T; Winthrop K; Baddley JW; Curtis JR
    Ann Rheum Dis; 2015 Jun; 74(6):1065-71. PubMed ID: 24608404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis.
    Hazlewood GS; Barnabe C; Tomlinson G; Marshall D; Devoe D; Bombardier C
    BMJ; 2016 Apr; 353():i1777. PubMed ID: 27102806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.
    Kristensen LE; Christensen R; Bliddal H; Geborek P; Danneskiold-Samsøe B; Saxne T
    Scand J Rheumatol; 2007; 36(6):411-7. PubMed ID: 18092260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.
    Alonso-Ruiz A; Pijoan JI; Ansuategui E; Urkaregi A; Calabozo M; Quintana A
    BMC Musculoskelet Disord; 2008 Apr; 9():52. PubMed ID: 18419803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events.
    Mendes D; Alves C; Batel-Marques F
    J Clin Pharm Ther; 2014 Jun; 39(3):307-13. PubMed ID: 24635532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
    Siddiqui MA
    Curr Opin Rheumatol; 2007 May; 19(3):308-13. PubMed ID: 17414961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.